A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM)
Year: 2006
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: H. A. Wakelee, A. A. Adjei, J. Halsey, J. L. Lensing, J. D. Dugay, L. J. Hanson, J. M. Reid, J. R. Piens, B. I. Sikic
Institutions: Mayo Clinic, Stanford University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2299072364